Mylan

Hurting for revenue, Mylan shells out $130M for basket of Aspen drugs
Hurting for revenue, Mylan shells out $130M for basket of Aspen drugs
Fierce Pharma
Mylan
Aspen Pharmacare
M&A
Australia
New Zealand
Flag link:
Medicaid misclassification bill inspired by EpiPen snafu passes Congress
Medicaid misclassification bill inspired by EpiPen snafu passes Congress
Fierce Pharma
Mylan
generics
EpiPen
Medicaid
congress
misclassification
Flag link:
After Alzheimer’s collapse, Biogen must win Tecfidera patent challenge
After Alzheimer’s collapse, Biogen must win Tecfidera patent challenge
EP Vantage
Biogen
Alzheimer's disease
Tecfidera
generics
Mylan
Flag link:
Mylan and Hospira both recall injected drugs after particulate discovered in vials
Mylan and Hospira both recall injected drugs after particulate discovered in vials
Fierce Pharma
Mylan
Hospira
recalls
diabetes
chemotherapy
Flag link:
Mylan's Advair generic pressures GSK with strong launch
Mylan's Advair generic pressures GSK with strong launch
BioPharma Dive
GSK
Mylan
generics
Advair
Wixela Inhub
Flag link:
What's Behind Mylan's Disappointing Q4 Earnings?
What's Behind Mylan's Disappointing Q4 Earnings?
Motley Fool
Mylan
earnings
Flag link:
Teva aims for 25% of U.S. EpiPen market by 2020
Teva aims for 25% of U.S. EpiPen market by 2020
Drug Delivery Business News
Teva Pharmaceutical
Mylan
EpiPen
generics
Flag link:
Mylan launches Advair generic at 70% discount in US
Mylan launches Advair generic at 70% discount in US
Pharmaforum
Mylan
GSK
Advair
generics
Flag link:
Mylan takes step toward knocking down key patent for Biogen's top-seller
Mylan takes step toward knocking down key patent for Biogen's top-seller
Biopharma Dive
Mylan
Biogen
Tecfidera
patents
inter partes review
Flag link:
Mylan’s Generic Advair Breathes New Life into Asthma Market
Mylan’s Generic Advair Breathes New Life into Asthma Market
Xtalks
Mylan
GSK
Advair
generics
FDA
asthma
Wixela Inhub
Flag link:
Mylan finally crosses the finish line with long-awaited generic of GlaxoSmithKline's Advair
Mylan finally crosses the finish line with long-awaited generic of GlaxoSmithKline's Advair
Fierce Pharma
Mylan
GSK
FDA
Advair
generics
Wixela Inhub
Flag link:
UnitedHealthcare, fueled by federal probes, sues generics makers for price fixing
UnitedHealthcare, fueled by federal probes, sues generics makers for price fixing
Fierce Pharma
UnitedHealthcare
generics
price fixing
drug pricing
Mylan
Teva Pharmaceuticals
Sandoz
Actavis
Par Pharmaceutical
Sun Pharma
Aurobindo
Taro Pharmaceuticals
Flag link:
Adamis stock surges on release of EpiPen alternative
Adamis stock surges on release of EpiPen alternative
Marketwatch
Adamis
Mylan
Sandoz
EpiPens
Symjepi
Flag link:
Ironwood, Allergan set to resolve LINZESS patent litigation with Mylan
Ironwood, Allergan set to resolve LINZESS patent litigation with Mylan
Pharmaceutical Business Review
Ironwood Pharmaceuticals
Mylan
patents
Linzess
Flag link:
Sandoz prepares early 2019 launch for EpiPen alternative Symjepi at 16% discount
Sandoz prepares early 2019 launch for EpiPen alternative Symjepi at 16% discount
Fierce Pharma
Novartis
Sandoz
generics
Symjepi
EpiPens
Teva Pharmaceutical
Mylan
Flag link:
Teva launches EpiPen generic at same price as Mylan's version
Teva launches EpiPen generic at same price as Mylan's version
Biopharma Dive
Teva Pharmaceutical
Mylan
EpiPens
generics
Flag link:
Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years
Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years
BioSpace
cancer
breast cancer
lung cancer
drug approvals
AstraZeneca
Takeda
Ariad Pharmaceuticals
Merck
Pfizer
Novartis
Boehringer Ingelheim
Bristol-Myers Squibb
Eli Lilly
Puma Biotechnology
Mylan
Genentech
Flag link:
Mylan, Theravance win FDA approval for COPD drug
Mylan, Theravance win FDA approval for COPD drug
Biopharma Dive
Theravance
Mylan
Yupelri
COPD
FDA
Flag link:
Mylan N.V. Improves in the Third Quarter Thanks to International Sales
Mylan N.V. Improves in the Third Quarter Thanks to International Sales
Motley Fool
Mylan
earnings
Flag link:
Coherus looks to disrupt Amgen’s $4B Neulasta franchise as analysts look for a deep discount on its copycat price
Coherus looks to disrupt Amgen’s $4B Neulasta franchise as analysts look for a deep discount on its copycat price
Endpoints
Coherus
Neulasta
Mylan
biosimilars
Amgen
Flag link:

Pages